ABSTRACT: Background and purpose: A putative novel cannabinoid receptor mediates vasorelaxation to anandamide and abnormal-cannabidiol and is blocked by O-1918 and by high concentrations of rimonabant. This study investigates VSN16, a novel water-soluble agonist, as a vasorelaxant potentially acting at non-CB1, non-CB2 cannabinoid receptors in the ... Continue Reading
O-1918
STUDY: Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor
ABSTRACT: Oleamide (cis-9-octadecenoamide) exhibits some cannabimimetic responses despite its low affinities at the currently known cannabinoid receptors. Here we have investigated whether or not it is a vasorelaxant in rat small mesenteric arteries. Oleamide elicited vasorelaxation (EC50=1.2±0.2 μm, Rmax=99.1±3.9%, n=8) which was reduced by endothelial removal. ... Continue Reading
STUDY: Lung Carcinoma – Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product
ABSTRACT: Background and purpose: The endocannabinoid virodhamine is a partial agonist at the cannabinoid CB1 receptor and a full agonist at the CB2 receptor, and relaxes rat mesenteric arteries through endothelial cannabinoid receptors. Its concentration in the periphery exceeds that of the endocannabinoid anandamide. Here, we examined the influence of virodhamine on the ... Continue Reading
STUDY: A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats
ABSTRACT: Background and purpose: Intravenous injection of the endocannabinoid anandamide induces complex cardiovascular changes via cannabinoid CB1, CB2 and vanilloid TRPV1 receptors. Recently, evidence has been accumulating that in vitro, but not in vivo, anandamide relaxes blood vessels, via an as yet unidentified, non-CB1 vascular cannabinoid receptor, sensitive to ... Continue Reading